These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35108650)

  • 1. Compound screening identified gossypetin and isoquercitrin as novel inhibitors for amyloid fibril formations of Vλ6 proteins associated with AL amyloidosis.
    Takahashi D; Matsunaga E; Yamashita T; Caaveiro JMM; Abe Y; Ueda T
    Biochem Biophys Res Commun; 2022 Mar; 596():22-28. PubMed ID: 35108650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of O-glycosylation on amyloid fibril formation of the variable domain in the Vλ6 light chain mutant Wil.
    Abe Y; Shibata H; Oyama K; Ueda T
    Int J Biol Macromol; 2021 Jan; 166():342-351. PubMed ID: 33127550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of amyloid fibril formation in the variable domain of λ6 light chain mutant Wil caused by the interaction between its unfolded state and epigallocatechin-3-O-gallate.
    Abe Y; Odawara N; Aeimhirunkailas N; Shibata H; Fujisaki N; Tachibana H; Ueda T
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2570-2578. PubMed ID: 30251653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual structures in the acid-unfolded states of Vlambda6 proteins affect amyloid fibrillation.
    Mishima T; Ohkuri T; Monji A; Kanemaru T; Abe Y; Ueda T
    J Mol Biol; 2009 Oct; 392(4):1033-43. PubMed ID: 19647748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational and genetic determinants of λ6 light chain amyloidogenesis.
    González-Andrade M; Becerril-Luján B; Sánchez-López R; Ceceña-Álvarez H; Pérez-Carreón JI; Ortiz E; Fernández-Velasco DA; del Pozo-Yauner L
    FEBS J; 2013 Dec; 280(23):6173-83. PubMed ID: 24107228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single mutation at the sheet switch region results in conformational changes favoring lambda6 light-chain fibrillogenesis.
    Hernández-Santoyo A; del Pozo Yauner L; Fuentes-Silva D; Ortiz E; Rudiño-Piñera E; Sánchez-López R; Horjales E; Becerril B; Rodríguez-Romero A
    J Mol Biol; 2010 Feb; 396(2):280-92. PubMed ID: 19941869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Light Chain 6aJL2-R24G Amyloid Fiber Formation Associated with Light Chain Amyloidosis.
    Pelaez-Aguilar AE; Rivillas-Acevedo L; French-Pacheco L; Valdes-Garcia G; Maya-Martinez R; Pastor N; Amero C
    Biochemistry; 2015 Aug; 54(32):4978-86. PubMed ID: 26214579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.
    Radamaker L; Lin YH; Annamalai K; Huhn S; Hegenbart U; Schönland SO; Fritz G; Schmidt M; Fändrich M
    Nat Commun; 2019 Mar; 10(1):1103. PubMed ID: 30894526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity.
    Wall J; Schell M; Murphy C; Hrncic R; Stevens FJ; Solomon A
    Biochemistry; 1999 Oct; 38(42):14101-8. PubMed ID: 10529258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation.
    Peterle D; Klimtchuk ES; Wales TE; Georgescauld F; Connors LH; Engen JR; Gursky O
    J Mol Biol; 2021 Dec; 433(24):167310. PubMed ID: 34678302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
    Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
    Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing.
    Kimura K; Tsukamoto S; Miyazaki K; Kawajiri-Manako C; Ishii A; Rahmutulla B; Fukuyo M; Oshima-Hasegawa N; Mitsukawa S; Takeda Y; Mimura N; Takeuchi M; Ohwada C; Iseki T; Matsusaka K; Sanada M; Yokote K; Kaneda A; Ishida T; Suzuki K; Nakaseko C; Sakaida E
    Exp Hematol; 2021 Sep; 101-102():34-41.e4. PubMed ID: 34411686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
    Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
    Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the role of λ6 immunoglobulin light chain dimerization in amyloid formation.
    Wolwertz ML; Nguyen PT; Quittot N; Bourgault S
    Biochim Biophys Acta; 2016 Apr; 1864(4):409-18. PubMed ID: 26802902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and energetic basis of overrepresented λ light chain in systemic light chain amyloidosis patients.
    Zhao J; Zhang B; Zhu J; Nussinov R; Ma B
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2294-2303. PubMed ID: 29241665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism for retardation of amyloid fibril formation by sugars in Vλ6 protein.
    Abe M; Abe Y; Ohkuri T; Mishima T; Monji A; Kanba S; Ueda T
    Protein Sci; 2013 Apr; 22(4):467-74. PubMed ID: 23389799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains.
    Rottenaicher GJ; Weber B; Rührnößl F; Kazman P; Absmeier RM; Hitzenberger M; Zacharias M; Buchner J
    J Biol Chem; 2021; 296():100334. PubMed ID: 33508322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin light chain amyloid aggregation.
    Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
    Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
    Bhutani D; Leng S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.
    Wall JS; Gupta V; Wilkerson M; Schell M; Loris R; Adams P; Solomon A; Stevens F; Dealwis C
    J Mol Recognit; 2004; 17(4):323-31. PubMed ID: 15227639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.